title: Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison.
abstract: Bendamustine and ibrutinib are commonly used in the treatment of patients suffering from chronic lymphocytic leukemia (CLL). In this study we compare efficacy and safety bendamustine versus ibrutinib therapy in previously untreated patients with CLL. Because there are no head-to-head comparisons between bendamustine and ibrutinib, we performed indirect comparison using Bucher method. A systematic literature review was performed and 2 studies published before June 2016 were taken into analysis. Treatment with ibrutinib significantly improves PFS determined by investigator (HR of 0.3; P = .01) and OS (HR of 0.21; P < .001. Our study indicates that ibrutinib therapy improves PFS, OS and is superior in terms of safety comparing with bendamustine therapy in CLL patients.
authors.affiliation: WroMedica Research Center, Wroclaw, Poland. Electronic address: igaandrasiak@gmail.com.
authors.forename: Iga
authors.initials: I
authors.lastname: Andrasiak
authors.affiliation: Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University, Wroclaw, Poland.
authors.forename: Justyna
authors.initials: J
authors.lastname: Rybka
authors.affiliation: Clinical Department of Hematology, Independent Public Healthcare Facility of the Ministry of Internal Affairs With Warmia and Mazury Oncology Centre, Olsztyn, Poland.
authors.forename: Wanda
authors.initials: W
authors.lastname: Knopinska-Posluszny
authors.affiliation: Department of Haematology, Blood Neoplasms and Bone Marrow Transplantation, Medical University, Wroclaw, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Wrobel
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality; D010880:Piperidines; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D000069461:Bendamustine Hydrochloride; D000225:Adenine
keywords: Bendamustine; CLL; First line of treatment; Ibrutinib; Indirect comparison